Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Holmberg

Showing results (81-90 of 287) with videos related to

Pageof 29
Sort By:
Journal of Clinical Epidemiology|December 20, 2022
Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidenceMarcus Westerberg, Kerri Beckmann, Rolf Gedeborg, et al.
European Urology Oncology|May 18, 2019
Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized TrialEva Johansson, Gunnar Steineck, Lars Holmberg, et al.
Scandinavian Journal of Urology and Nephrology|March 8, 2003
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2Amir Sherif, Erkki Rintala, Oddvar Mestad, et al.
European Urology|March 24, 2004
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studiesAmir Sherif, Lars Holmberg, Erkki Rintala, et al.
Breast Cancer Research and Treatment|June 15, 2011
Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnosesVoralak Vichapat, Hans Garmo, Lars Holmberg, et al.
BJU International|January 22, 2015
Causes of death in men with localized prostate cancer: a nationwide, population-based studyMieke Van Hemelrijck, Yasin Folkvaljon, Jan Adolfsson, et al.
Scandinavian Journal of Urology|March 14, 2024
Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control studyMats Ahlberg, Hans Garmo, Pär Stattin, et al.
BMC Medical Informatics and Decision Making|February 9, 2022
Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish malesMieke Van Hemelrijck, Eugenio Ventimiglia, David Robinson, et al.
Journal of Cancer Epidemiology|September 13, 2012
Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS StudyWahyu Wulaningsih, Hans Garmo, Lars Holmberg, et al.
BJU International|October 27, 2015
Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapySean O'Farrell, Karin Sandström, Hans Garmo, et al.
Pageof 29

Showing results (81-90 of 287) with videos related to

Sort By:
Pageof 29
Journal of Clinical Epidemiology|December 20, 2022
Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidenceMarcus Westerberg, Kerri Beckmann, Rolf Gedeborg, et al.
European Urology Oncology|May 18, 2019
Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized TrialEva Johansson, Gunnar Steineck, Lars Holmberg, et al.
Scandinavian Journal of Urology and Nephrology|March 8, 2003
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2Amir Sherif, Erkki Rintala, Oddvar Mestad, et al.
European Urology|March 24, 2004
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studiesAmir Sherif, Lars Holmberg, Erkki Rintala, et al.
Breast Cancer Research and Treatment|June 15, 2011
Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnosesVoralak Vichapat, Hans Garmo, Lars Holmberg, et al.
BJU International|January 22, 2015
Causes of death in men with localized prostate cancer: a nationwide, population-based studyMieke Van Hemelrijck, Yasin Folkvaljon, Jan Adolfsson, et al.
Scandinavian Journal of Urology|March 14, 2024
Triggers for transition from active surveillance to radical treatment of prostate cancer 2008-2020 - a case-control studyMats Ahlberg, Hans Garmo, Pär Stattin, et al.
BMC Medical Informatics and Decision Making|February 9, 2022
Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish malesMieke Van Hemelrijck, Eugenio Ventimiglia, David Robinson, et al.
Journal of Cancer Epidemiology|September 13, 2012
Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS StudyWahyu Wulaningsih, Hans Garmo, Lars Holmberg, et al.
BJU International|October 27, 2015
Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapySean O'Farrell, Karin Sandström, Hans Garmo, et al.
Pageof 29